Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

In the latest ASCO in Action Podcast, Dr. Jeffery Ward joins ASCO CEO Dr. Clifford A. Hudis to discuss utilization management (UM) policies and how these practices affect both patients and providers. Step therapy, also known as fail-first, is a UM practice that requires patients to try and fail on a lower-cost drug before obtaining the more expensive drug prescribed by their physician. Dr. Ward expresses concern about using step therapy in oncology care, as most people with cancer have a single best drug for their diagnosis and drug equivalence in cancer treatment is rare.
For many oncology patients, the home setting is typically a place for recovery following treatment for cancer. At times, this recovery is supported with formal home care services such as nurse and physical therapy visits, infusion services, and so forth. In the latest blog post, The Hospital at Home: A Bright Prospect for Oncology Care? Heather Hylton, MS, PA-C, examines this innovative paradigm that could enable patients to receive acute care in the home setting.
ASCO recently urged Congress to work with the Administration to adopt high-quality pathways, reduce the administrative burden of utilization management practices, and other ideas to improve the quality of cancer care in the United States. The comments are in response to a request for information from the Chairman of the Senate Health, Education, Labor, and Pensions Committee on reducing health care costs.
On the latest ASCO in Action Podcast, Dr. Lowell Schnipper, chair of ASCO’s Value of Cancer Care Task Force, joins ASCO CEO Dr. Clifford A. Hudis to discuss a joint assessment of value frameworks from ASCO and the European Society for Medical Oncology (ESMO). During the discussion, Dr. Schnipper says the assessment came about as ASCO and ESMO became aware of ‘overwhelming similarities’ between their frameworks.
Cancer.Net Mobile, an award-winning app, is an interactive Spanish-enabled tool that helps patients keep track of questions to ask their health care team, save information about their prescriptions, track symptoms and side effects, and much more, no matter where they are. Now featuring a new user interface and “My Health” Dashboard.
Do your patients know that palliative care can help them manage their symptoms and side effects, regardless of age, cancer type, or stage? Make sure your patients understand the benefits of palliative care and where to access services with the ASCO Answers Palliative Care booklet. A pack of 50 booklets costs $20 (that’s only $0.40 per booklet). ASCO Members save 20%. ASCO Answers products ship for free inside the U.S.
The Director of the National Cancer Institute (NCI) Dr. Ned Sharpless joins ASCO CEO Dr. Clifford  A. Hudis in the latest ASCO in Action Podcast to discuss modernizing clinical trials, maximizing big data, building the cancer research workforce, and NCI’s central role in leading cancer research. “The scale and scope of the NCI is truly both awe-inspiring and in some ways daunting,” says Dr. Sharpless of his first year at the NCI.
Share your QI strategies and best practices by submitting manuscripts demonstrating your pioneering projects. The Quality in Action category of content in JOP demonstrates the application of improvement science techniques in oncology practice. Papers are published as MEDLINE-indexed online articles. Learn more and submit to JOP.